Rémy Luthringer

Rémy is an advisor to the Medicxi investment team and a member of the co-founding team. He has played an active role in several Index Ventures and Medicxi portfolio companies to support their development, including Minerva Neurosciences (NASDAQ: NERV), Linguaflex, Kaerus, V-Watch, Orexia and Inexia. Rémy is Chairman, CEO and Chief Scientific Officer of Minerva Neurosciences (NASDAQ: NERV). Previously, he was the President and CEO of the Forenap Group, a research organization in neurosciences and drug development based in France.

Rémy is the author of around 50 publications, has been involved in the development of more than 150 central nervous system (CNS)  active molecules and has overseen more than 700 clinical trials.

Rémy received a PhD in Neurosciences and a PhD in Clinical Pharmacology, both from the University of Strasbourg.